ライフサイエンスコーパス: insulin-like growth factor

1 ng roles for cancer progression, such as the insulin-like growth factors.

2 itro, resulting in higher bioavailability of insulin-like growth factors.

3 To determine the roles of insulin and insulin-like growth factor 1 (IGF-1) action in adipose t

4 Insulin-like growth factor 1 (IGF-1) administration incr

5 transcription factor, resulting in enhanced insulin-like growth factor 1 (IGF-1) expression and acti

6 Human insulin-like growth factor 1 (IGF-1) is a 70 amino acid

7 Insulin-like Growth Factor 1 (IGF-1) is associated with

8 Insulin-like growth factor 1 (IGF-1) is known to have di

9 The hormonal actions of insulin-like growth factor 1 (IGF-1) produced by the liv

10 that feeding-regulated hormones insulin and insulin-like growth factor 1 (IGF-1) reset circadian clo

11 t or energy levels-most notably, the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway,

12 nction through the regulation of the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway.

13 also requires nutritionally induced insulin/insulin-like growth factor 1 (IGF-1) signalling (IIS) vi

14 liferation by modulating a decrease in serum insulin-like growth factor 1 (IGF-1) that allows GH rele

15 Finally, we studied the impact of insulin-like growth factor 1 (IGF-1) treatment on CDKL5

16 Serum levels of insulin-like growth factor 1 (IGF-1), a hormone with kno

17 pe 2 diabetes mellitus (T2DM) via binding of insulin-like growth factor 1 (IGF-1), an insulin-like ho

18 ng serum concentrations of glucose, insulin, insulin-like growth factor 1 (IGF-1), insulin-like growt

19 We previously established that an insulin-like growth factor 1 (IGF-1)-inducible mitochond

20 y, and low circulating levels of insulin and insulin-like growth factor 1 (IGF-1).

21 gate (MTA) showed an increased expression of insulin-like growth factor 1 (IGF-1).

22 n-associated cytokines, macrophages released insulin-like growth factor 1 (IGF-1).

23 o-expression of two soluble proteins, namely insulin-like growth factor 1 (IGF1) and osteopontin (OPN

24 sts expressed increased transcript levels of insulin-like growth factor 1 (Igf1) and the antimicrobia

25 lloprotease, Pappaa stimulates extracellular insulin-like growth factor 1 (IGF1) bioavailability.

26 ingly, treatment of RTT-derived neurons with Insulin-like Growth Factor 1 (IGF1) could rescue some of

27 novel MALDImmunoassay for quantification of insulin-like growth factor 1 (IGF1) in human plasma.

28 Insulin-like growth factor 1 (IGF1) is a key positive re

29 Insulin-like growth factor 1 (IGF1) is primarily synthes

30 Third, we uncovered that insulin-like growth factor 1 (IGF1) is produced by tumor

31 Insulin-like growth factor 1 (IGF1) is secreted in an au

32 receptor tyrosine kinases by neuregulin and insulin-like growth factor 1 (IGF1) leads to the phospho

33 AKT activation can be promoted by insulin-like growth factor 1 (IGF1) or insulin via a pat

34 proteins to autophosphorylation sites in the insulin-like growth factor 1 (IGF1) receptor (IGF1R).

35 ic species with high binding affinity to the insulin-like growth factor 1 (IGF1) receptor.

36 ffects of (56)Fe radiation on adipokines and insulin-like growth factor 1 (IGF1) signaling axis in mo

37 Evidence suggests Insulin-like growth factor 1 (IGF1) signaling is involve

38 e neonatal airway where stromal cell-derived insulin-like growth factor 1 (IGF1) supports the prolife

39 Human fibroblast growth factor 2 (FGF2) and insulin-like growth factor 1 (IGF1), are canonical proto

40 Alveolar fibroblasts produced insulin-like growth factor 1 (IGF1), which instructed ex

41 n, or co-overexpression of osteopontin (OPN)/insulin-like growth factor 1 (IGF1)/ciliary neurotrophic

42 cer pinpoint to a potential new function for insulin-like growth factor 1 (Igf1r) in the basal epithe

43 tic effects of potent growth factors such as insulin-like growth factor 1 and basic fibroblast growth

44 ands, and feet and are diagnosed by elevated insulin-like growth factor 1 levels and growth hormone l

45 f GH excess including significantly elevated insulin-like growth factor 1 levels, larger weight and b

46 bolism, such as suppression of production of insulin-like growth factor 1 or growth hormone, are invo

47 Supplementation of insulin-like growth factor 1 partially reverted the DR-i

48 the insulin receptor (F-IRKO) or both IR and insulin-like growth factor 1 receptor (F-IR/IGFRKO).

49 atric skin display reduced activation of the insulin-like growth factor 1 receptor (IGF-1R) and alter

50 iates for the activation of PI3K by both the insulin-like growth factor 1 receptor (IGF-1R) and its c

51 Here, we found in the mouse that the insulin-like growth factor 1 receptor (IGF-1R) controls

52 rs revealed 6ha as preferential inhibitor of insulin-like growth factor 1 receptor (IGF-1R) in a pane

53 mice expressing a mutated form of the human insulin-like growth factor 1 receptor (IGF-1R) in skelet

54 We have previously shown that the insulin-like growth factor 1 receptor (IGF-1R) transloca

55 tor 2 (IGF2) gene, encoding a ligand for the insulin-like growth factor 1 receptor (IGF-1R), in a sub

56 ession in this lineage and was stimulated by insulin-like growth factor 1 receptor (IGF1R) activation

57 in asthma, but little is known about how the insulin-like growth factor 1 receptor (IGF1R) affects as

58 We demonstrate that the deletion of insulin-like growth factor 1 receptor (Igf1r) in mouse e

59 etibial myxoedema) involves the synergism of insulin-like growth factor 1 receptor (IGF1R) with TSHR

60 tent and functionally relevant activation of insulin-like growth factor 1 receptor (IGF1R), resulting

61 eduction of proangiogenic factors, including insulin-like growth factor 1 receptor (Igf1R).

62 we found that dual inhibition of MEK1/2 and insulin-like growth factor 1 receptor (IGF1R)/insulin re

63 nt mannose 6-phosphate receptor (CI-MPR) and Insulin-like growth factor 1 receptor (IGF1R); however,

64 al RKRR motif(2) from the alpha-chain of the insulin-like growth factor 1 receptor that is critical f

65 2 (Cyclin D2), CCND1 (Cyclin D1), and IGF1R (insulin-like growth factor 1 receptor) genes involved in

66 t-mammalian target of rapamycin pathway, and insulin-like growth factor 1 receptor-targeted therapy h

67 gans strains with mutations in daf-2/insulin/insulin-like growth factor 1 receptor.

68 Insulin-like growth factor 1 signaling in tenocytes is r

69 hanges in microRNA levels regulate SIRT1 and insulin-like growth factor 1 signalling.

70 IGF-1 (insulin-like growth factor 1) expression was increased a

71 indings included a protective role of IGF-1 (insulin-like growth factor 1) in systolic blood pressure

72 ar myocytes blocked phenylephrine- and IGF1 (insulin-like growth factor 1)-mediated RHEB induction, m

73 physiological hypertrophy induced by IGF-1 (insulin-like growth factor 1).

74 ion and loss-of-function mutations affecting insulin-like growth factor 1, fibroblast growth factor r

75 story, medications, and laboratory findings (insulin-like growth factor 1, follicle-stimulating hormo

76 eased expression of pro-regenerative factors insulin-like growth factor 1, leukemia inhibitory factor

77 Secondary outcomes included fasting insulin-like growth factor 1, lipids, glucose, insulin,

78 ne cardiomyocyte proliferation stimulated by insulin-like growth factor 1, this effect is mediated vi

79 model assessment of insulin resistance, and insulin-like growth factor 1.

80 pinal cord, and normalization of circulating insulin-like growth factor 1.

81 associated with higher mean levels of IGF1 (insulin-like growth factor 1; hazard ratio per 1 SD incr

82 Information on how insulin and insulin-like growth factors 1 and 2 (IGF-1 and -2) activ

83 MSCs exhibited >25x higher secretion of IGF (insulin-like growth factor)-1 compared with failing hMSC

84 However, the possible roles of the insulin like growth factor-1 receptor (IGF-1R) on neuron

85 growth while suppressing the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

86 entified dysregulation of the Growth Hormone/Insulin-like Growth Factor-1 (GH/IGF-1) pathway as well

87 In addition to IRBP, the IPM also contains insulin-like growth factor-1 (IGF-1) and its associated

88 scular endothelial growth factor-A (VEGF-A), insulin-like growth factor-1 (IGF-1) and Klotho, in the

89 Insulin-like growth factor-1 (IGF-1) and signal transduc

90 recurrent GBM, driven by macrophage-derived insulin-like growth factor-1 (IGF-1) and tumor cell IGF-

91 ransforming Growth Factor Beta (TGFbeta) and insulin-like growth factor-1 (IGF-1) are known to promot

92 e previously shown that systemic infusion of insulin-like growth factor-1 (IGF-1) exerts anti-inflamm

93 (PFNA), may alter levels of sex hormones and insulin-like growth factor-1 (IGF-1) in animals.

94 Exogenous Insulin-Like Growth Factor-1 (IGF-1) is neuroprotective

95 High circulating insulin-like growth factor-1 (IGF-1) levels increase the

96 e MC4R, we assessed pulsatile GH release and insulin-like growth factor-1 (IGF-1) production and/or r

97 Activation of insulin-like growth factor-1 (IGF-1) receptor (IGF1R) si

98 In contrast, mice pretreated with insulin-like growth factor-1 (IGF-1) showed resolution o

99 mediates adipogenesis and show a link to the insulin-like growth factor-1 (IGF-1) signaling pathway.

100 ells secrete a subthreshold concentration of insulin-like growth factor-1 (IGF-1) that primes the IGF

101 VEGF-D), ETS-related gene protein (ERG), and insulin-like growth factor-1 (IGF-1) were measured simul

102 Interestingly, (1-3) insulin-like growth factor-1 (IGF-1), a small peptide un

103 eride) (PEAD) polycation, heparin, and cargo insulin-like growth factor-1 (IGF-1), in thiolated gelat

104 ce (95% CI) was computed for levels of serum insulin-like growth factor-1 (IGF-1), leptin, and adipon

105 ker proteins ETS-related gene protein (ERG), insulin-like growth factor-1 (IGF-1), pigment epithelial

106 elaborates the cardioprotective polypeptide, insulin-like growth factor-1 (IGF-1), which activates IG

107 Lin28-treated retinas responded to insulin-like growth factor-1 (IGF1) by initiating retina

108 ion and proliferation as well as insulin and insulin-like growth factor-1 (IGF1) receptor activation

109 actors released by astrocytes as insulin and insulin-like growth factor-1 (IGF1).

110 secretion of paracrine mediators, including insulin-like growth factor-1 (IGF1).

111 d-beta plaques and expressed 3.2-fold higher insulin-like growth factor-1 (P < 0.01) and ~60% lower t

112 , SP and its metabolites in combination with insulin-like growth factor-1 are shown to promote the co

113 Perfluoroalkyl substances, sex hormones, and insulin-like growth factor-1 at 6-9 years of age: a cros

114 gonists which led to a sustained increase of insulin-like growth factor-1 in a dog pharmacodynamic st

115 Macrophage-derived insulin-like growth factor-1 is a key neurotrophic and n

116 Insulin-like growth factor-1 levels in quartile 4 were n

117 Insulin-like growth factor-1 levels in quartile 4 were n

118 hormone secretion and subsequent increase of insulin-like growth factor-1 levels, an important mediat

119 anslocation to the nucleus was stimulated by insulin-like growth factor-1 or TGFbeta.

120 Elevated IGF-1/insulin-like growth factor-1 receptor (IGF-1R) autocrine

121 feration in P2 cardiomyocytes, by activating insulin-like growth factor-1 receptor (IGF-1R)-mediated

122 -regulation of two of its targets: BCL-2 and insulin-like growth factor-1 receptor (IGF1R).

123 kinases (RTK), including the cancer-relevant insulin-like growth factor-1 receptor (IGF1R).

124 mmunohistochemical positivity for p4E-BP1 or insulin-like growth factor-1 receptor was statistically

125 of the prefusion RSV-F glycoprotein with the insulin-like growth factor-1 receptor, triggers the acti

126 Treatment with recombinant human insulin-like growth factor-1 restores responses of PV(+)

127 agy gene, and observed deficient insulin and insulin-like growth factor-1 signaling.

128 Impaired insulin/insulin-like growth factor-1 signalling (IGF-1) and insu

129 acronutrients, milk contains calcium and the insulin-like growth factor-1 that are of major relevance

130 -6 and -10, tumor necrosis factor-alpha, and insulin-like growth factor-1 were not found to be associ

131 2 saturation and plasma glucose, insulin and insulin-like growth factor-1 were positively associated

132 IGF-1 (insulin-like growth factor-1) is markedly decreased in n

133 (lipid X receptor), the growth factor IGF1 (insulin-like growth factor-1), and the splenic red pulp

134 ich was amplified by MCL-specific cytokines (insulin-like growth factor-1, B-cell activating factor,

135 or-alpha), pro-healing immune profiles (high insulin-like growth factor-1, elongated cell morphology)

136 LR2 deficiency also affected milk content of insulin-like growth factor-1, IFN-gamma, IL-6, and IL-13

137 changes including altered levels of insulin, insulin-like growth factor-1, leptin, adiponectin, stero

138 This potentiation is produced by insulin-like growth factor-1, whose binding proteins are

139 emoattractant protein-1, IL-6, IL-1beta, and insulin-like growth factor-1.

140 5190457 were acyl-to-total ghrelin ratio and insulin-like growth factor-1.

141 Adaptor proteins in the insulin/insulin-like-growth factor-1 signaling pathways, such as

142 nockdown cells was associated with increased insulin-like growth factor- 1Rbeta (IGF-1Rbeta) levels.

143 mouse hippocampus, induces the expression of insulin-like growth factor 2 (IGF2) for the stabilizatio

144 nt hypomethylation of an enhancer within the insulin-like growth factor 2 (IGF2) gene in major psycho

145 s Network detected the overexpression of the insulin-like growth factor 2 (IGF2) gene, encoding a lig

146 We addressed this question at the H19/insulin-like growth factor 2 (Igf2) imprinted locus, the

147 Insulin-like growth factor 2 (IGF2) is the major fetal g

148 IMPs, also known as insulin-like growth factor 2 (IGF2) messenger RNA (mRNA)

149 Insulin-like growth factor 2 (IGF2) mRNA binding protein

150 activating enzyme, deiodinase-III (Dio3) and insulin-like growth factor 2 (Igf2), genes that are know

151 in the small dysfunctional placenta in FGR [insulin-like growth factor 2 knockout (P0) mouse model o

152 The gene encoding the Insulin-like Growth Factor 2 mRNA binding protein 2/IMP2

153 f the heterochronic let-7 miRNA pathway, the insulin-like growth factor 2 mRNA-binding protein 1 (IGF

154 Insulin-like growth factor 2 mRNA-binding protein 1 (IGF

155 Insulin-like growth factor 2 mRNA-binding protein 1 (IGF

156 Global deletion of the mRNA-binding protein insulin-like growth factor 2 mRNA-binding protein 2 (IGF

157 Here, we determined that the RBP insulin-like growth factor 2 mRNA-binding protein 3 (IGF

158 Insulin-like growth factor 2 mRNA-binding proteins 1-3 (

159 Here we report that VKORC1v2 associates with insulin-like growth factor 2 receptor (IGF2R), also know

160 ion in mutants exhibiting aberrant H19/Igf2 (insulin-like growth factor 2) imprinting.

161 or necrosis factor alpha and lower levels of insulin-like growth factor 2.

162 ts known ability to promote the abundance of Insulin-like Growth Factor 2/IGF2, we find that IMP2 str

163 IMP3 (insulin-like growth factor-2 mRNA binding protein 3) is

164 The insulin-like growth factor-2 mRNA-binding protein 1 (IGF

165 The consistent surface overexpression of insulin-like growth factor-2 receptor (IGF2R) has been r

166 The cation-independent mannose 6-phosphate/insulin-like growth factor-2 receptor (M6P/IGF2R or IGF2

167 acellular domains of the mannose 6-phosphate/insulin-like growth factor-2 receptor (M6P/IGF2R), domai

168 ing indicated substantial down-regulation of insulin-like growth factor binding protein (Igfbp) genes

169 Insulin-like growth factor binding protein (IGFBP)-1 inf

170 tor (PDGF) isoforms (PDGF-AA, -BB, and -AB), insulin-like growth factor binding protein (IGFBP)-2, an

171 Low circulating levels of insulin-like growth factor binding protein 1 (IGFBP-1) a

172 Insulin-like growth factor binding protein 1 (IGFBP-1) i

173 enes involved in embryonic neurodevelopment: insulin-like growth factor binding protein 2 ( IGFBP2),

174 Recent studies suggest that insulin-like growth factor binding protein 2 (IGFBP-2) m

175 Insulin-like growth factor binding protein 2 (IGFBP2) is

176 sulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3),

177 K regulates Runx1-dependent transcription of insulin-like growth factor binding protein 3 (IGFBP3), a

178 ase plasminogen activator receptor), IGFBP7 (insulin-like growth factor binding protein 7), and GDF-1

179 In this setting, the insulin-like growth factor binding protein IGFBP7 inhibi

180 Insulin-like growth factor binding protein-3 (IGFBP-3) b

181 Reduction of prolactin, insulin-like growth factor binding protein-3, and matrix

182 hibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor binding protein-7 (IGFBP7) ha

183 Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)" ro

184 sion, including an increase in stress marker insulin-like growth factor-binding protein 1 (IGFBP-1),

185 esponse elements located in the promoters of insulin-like growth factor-binding protein 1 (IGFBP1) an

186 ated with higher mean levels of both IGFBP1 (insulin-like growth factor-binding protein 1; hazard rat

187 ein 4, Plasminogen activator inhibitor 1 and Insulin-like growth factor-binding protein 2) with a pre

188 aminoacylase-1, growth hormone receptor, and insulin-like growth factor-binding protein 2.

189 Higher levels of insulin-like growth factor-binding protein 3 (IGFBP-3) m

190 The regulation of insulin-like growth factor-binding protein 3 (IGFBP3) ge

191 sure; cFn (cellular fibronectin) and IGFBP3 (insulin-like growth factor-binding protein 3) were relat

192 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 ([TIMP-2] x

193 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 accurately

194 r, tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 and of rena

195 of tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 and renal r

196 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in patients

197 tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7 in response

198 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in this pop

199 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 results in

200 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 significant

201 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 test was no

202 nd tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 to predict

203 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 was 0.84 (0

204 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 was measure

205 ry tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 was not sig

206 of tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 was poor wi

207 ry tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 was unable

208 owed by a marker of cell cycle arrest (urine insulin-like growth factor-binding protein 7) and, final

209 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7.

210 [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] across the

211 [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] and signif

212 [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] between pr

213 [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] changes an

214 [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] increases

215 [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] were signi

216 RNA-seq analysis identified insulin-like growth factor-binding protein-5 (IGFBP-5) a

217 cancer model and decreased the expression of insulin-like growth factor-binding protein-5 (IGFBP5).

218 [C-telopeptide for type I collagen], IGFBP7 [insulin-like growth factor-binding protein-7], and GAL-3

219 Circulating insulin-like growth factor I (IGF-I) is positively assoc

220 Insulin and insulin-like growth factor I (IGF-I) signal through the

221 Disruption of insulin-like growth factor I (IGF-I) signaling is a key

222 AD in mice responds positively to decreased insulin-like growth factor I (IGF-I) signaling, a pathwa

223 ition and height growth, perhaps mediated by insulin-like growth factor I (IGF-I).

224 wel disease (IBD) present with reduced serum insulin-like growth factor I (IGF-I).

225 release of growth hormone and, consequently, insulin-like growth factor I (IGF1), most often by a pit

226 mini nutritional assessment (P = 0.003), and insulin-like growth factor I (P = 0.002), and lowered C-

227 Strong evidence has implicated the insulin-like growth factor I receptor (IGF-IR) in the pa

228 Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new

229 ved growth factor receptor beta (Pdgfrb) and insulin-like growth factor I receptor (Igf1r) on T-ALL c

230 ata from a candidate marker, we analyzed the insulin-like growth factor I receptor (IGF1R), a promisi

231 human epidermal growth factor, insulin, and insulin-like growth factor I, particularly at the parasi

232 bolic variables, including glucose, insulin, insulin-like growth factor I, triglycerides, cholesterol

233 Insulin and insulin-like growth factors I and II are closely related

234 GFBP)-1 influences fetal growth by modifying insulin-like growth factor-I (IGF-I) bioavailability.

235 l and neuropsychological recovery, and serum insulin-like growth factor-I (IGF-I) may mediate this ef

236 In the total population, insulin-like growth factor-I (IGF-I)-enhanced cell cycle

237 rafts in mice, along with reduction of tumor insulin-like growth factor-I and vascular endothelial gr

238 and structural homology between mature human insulin-like growth factors IGF-1 and IGF-2 makes serolo

239 backgrounds, including the long-lived daf-2/insulin like growth factor (IGF) receptor and short live

240 Growth-related glycoproteins insulin-like growth factor (IGF) 1, IGF binding protein-

241 e regulation of insulin secretion by insulin/insulin-like growth factor (IGF) 2-AKT signaling.

242 The insulin-like growth factor (IGF) axis may be implicated

243 Insulin-like growth factor (IGF) binding protein 2 (IGFB

244 stoma, is driven by Sonic hedgehog (Shh) and insulin-like growth factor (IGF) in the developing cereb

245 Signaling via the insulin-like growth factor (IGF) pathway is aberrantly a

246 The insulin-like growth factor (IGF) receptor (IGF-IR) is ne

247 Lowered insulin/insulin-like growth factor (IGF) signaling (IIS) can ext

248 Evolutionarily conserved insulin/insulin-like growth factor (IGF) signaling (IIS) has bee

249 hat maternal DR and reduced maternal insulin/insulin-like growth factor (IGF) signaling (IIS) increas

250 the sirtuin family of proteins, the insulin/insulin-like growth factor (IGF) signaling (IIS) pathway

251 The insulin/insulin-like growth factor (IGF) signaling pathway plays

252 Insulin-like growth factor (IGF) signaling plays an impo

253 study is the identification of mutations in insulin-like growth factor (IGF) signalling genes in 8/1

254 The insulin-like growth factor (IGF) system is a well-studie

255 The growth hormone and insulin-like growth factor (IGF) system is integral to h

256 , many of which display dysregulation of the insulin-like growth factor (IGF) system.

257 hlighted an enrichment of the "Regulation of Insulin-like Growth Factor (IGF) transport and uptake by

258 Cells were treated with T(3) (1.5 nm), insulin-like growth factor (IGF)-1 (1 mug mL(-1) ) or a

259 .0001), insulin (r(2) = 0.40, P < 0.005) and insulin-like growth factor (IGF)-1 (r(2) = 0.80, P < 0.0

260 -ERalphaKO along with higher serum levels of insulin-like growth factor (IGF)-1 as well as IGF-bindin

261 notype were accompanied by altered placental insulin-like growth factor (IGF)-2 expression and insuli

262 aintained the quiescent state by suppressing insulin-like growth factor (IGF)-mediated Akt-Tor and Er

263 Aberrant regulation of the insulin-like growth factor (IGF)/insulin (IIS)-PI3K-AKT-

264 , including Wnt/beta-catenin, Prolactin, and insulin-like growth factor (IGF)1 signaling.

265 growth factors (FGFs)-2 and -13, and type 1 insulin-like growth factor (IGF-1), which enhance neuron

266 ance of pancreatic cancer cells by secreting insulin-like growth factors (IGF) 1 and 2, which activat

267 oming a key regulator of metabolism, whereas insulin-like growth factors (IGF)-I/II are major growth

268 The insulin-like growth factors IGF1 and IGF2 are closely re

269 A focus on reversible mechanisms identified Insulin-like growth factor (IGF1) deficiency with inadeq

270 e gene that experiences LOI is the paracrine insulin-like growth factor IGF2, which occurs commonly i

271 Insulin-like growth factors (IGFs) are essential for loc

272 We show significant overexpression of insulin-like growth factors (IGFs) in association with I

273 This review discusses the role of the insulin-like growth factors (IGFs) in controlling placen

274 Insulin-like growth factors (IGFs) induce proliferation

275 Insulin-like growth factors (IGFs), specifically IGF1 an

276 a systemic administration of the polypeptide insulin-like growth factor II (IGF-II) reverses all thes

277 st the effects of systemic administration of insulin-like growth factor II (IGF-II), a polypeptide th

278 Insulin-like growth factor II (IGF2) enhances memory in

279 antagomir-352 up-regulated the expression of insulin-like growth factor II receptor (IGF2R), which ma

280 P94), a prominent ER chaperone known to fold insulin-like growth factors, in proinsulin handling with

281 ile hormone, 20-hydroxyecdysone, and insulin/insulin-like growth factor-like signaling in regulating

282 Hyperinsulinemia and higher insulin-like growth factors may increase breast cancer r

283 s of the transforming growth factor-beta and insulin-like growth factors pathways, and extracellular

284 Type 1 insulin-like growth factor receptor (IGF1R) is a recepto

285 Insulin-Like Growth Factor Receptor 1 (IGF-1R) and Epide

286 the MAPK pathway, PI3Kbeta, and PI3Kalpha or insulin-like growth factor receptor 1 (IGF1R) synergisti

287 RBB4 while revealing increased expression of insulin-like growth factor receptor 1 (IGF1R).

288 4 seems to exert RIBEs by acting through the insulin-like growth factor receptor DAF-2.

289 oward the insulin receptor and/or the type 1 insulin-like growth factor receptor.

290 to activate PI3K signaling downstream of the insulin-like growth factor receptor.

291 We further demonstrate that insulin like growth factor signaling may mediate the pro

292 Reduced activity of insulin/insulin-like growth factor signaling (IIS) and mechanist

293 Down-regulation of insulin/insulin-like growth factor signaling (IIS) can increase

294 o DNA damage repair, cell cycle progression, insulin-like growth factor signaling, innate immunity, a

295 Insulin/insulin-like growth factor signalling (IIS) is a critica

296 etabolic diseases and cancer are insulin and insulin-like growth factor signalling pathways.

297 nt mannose-6-phosphate receptor, also called insulin-like growth factor two receptor (CIM6P/IGF2R), p

298 inases, including the highly cancer relevant insulin-like growth factor type 1 receptor (IGF-1R).

299 Insulin-like growth factor type 2 (IGF2) receptor (IGF2R

300 eceptor isoforms A and B (IR-A and IR-B) and insulin-like growth factor type I receptor (IGF-1R).